ANALYSIS OF EXPRESSION OF HER-2 RECEPTOR IN GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMAS

Background: Gastric and gastroesophageal junction adenocarcinomas (GEAs) is associated with signicant morbidity and mortality due to early metastasis. HER2 receptor of the RAS-RAF-MAPK pathway and PI3K signalling pathway has been targeted successfully in breast carcinoma. The To GA trial shows signicant improvement in survival treated with trastzumab in patients with advanced or metastatic gastric and gastroesophal junction adenocarcinomas. We analyse the expression of HER2 receptor in patients with metastatic GEAs. Methods: This observational study was conducted at Indraprastha Apollo hospitals, New Delhi between july 2017 to june 2019 and included 70 patients who presented with metastatic gastroesophageal adenocarcinomas and to analyse if there is any correlation with respect to age, gender, location of the tumour, histological grade and Lauren classication. Results: Out of 70 patients, 9 patients had overexpression of HER2 (12.8%) by immunohistochemistry. HER2 overexpression is not signicantly different with respect to age, gender, location of the tumour, histological grade and Lauren classication. Conclusion: HER2 overexpression in gastric and gastroesophageal junction adenocarcinomas is seen in relatively low proportion of our patients and no specic patient and tumour characteristics could be identied where HER2 overexpression is more likely